

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference B 2286 PCT	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/EP 99/ 05405	International filing date (day/month/year) 28/07/1999	(Earliest) Priority Date (day/month/year) 29/07/1998
Applicant MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG D...et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.



It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.



the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :



contained in the international application in written form.



filed together with the international application in computer readable form.



furnished subsequently to this Authority in written form.



furnished subsequently to this Authority in computer readable form.



the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.



the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,



the text is approved as submitted by the applicant.



the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,



the text is approved as submitted by the applicant.



the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.



as suggested by the applicant.



because the applicant failed to suggest a figure.



because this figure better characterizes the invention.



None of the figures.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/05405

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07H19/167 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07H C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>PIGNOT, MARC; SIETHOFF, CHRISTOPH; LINSCHIED, MICHAEL; WEINHOLD, ELMAR: "Coupling of a nucleoside with DNA by a methyltransferase" ANGEW. CHEM., INT. ED., vol. 37, no. 20, 1998, pages 2888-91, XP002120745 the whole document</p> <p>---</p>	1-30
A	<p>MATTEUCCI, M. D.; WEBB, T. R.: "Synthesis and crosslinking properties of a deoxyoligonucleotide containing N6,N6-ethanodeoxyadenosine" TETRAHEDRON LETT., vol. 28, no. 22, 1987, pages 2469-72, XP002120746</p> <p>---</p> <p>-/--</p>	

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 October 1999

Date of mailing of the international search report

17/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bardili, W

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/05405

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MCCLELLAND, M.: "Purification and characterization of two new modification methylases" NUCLEIC ACIDS RES., vol. 9, no. 24, 1981, pages 6795-6804, XP002120747 cited in the application -----</p>	

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
 United States Patent and Trademark
 Office
 Box PCT
 Washington, D.C.20231
 ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 29 March 2000 (29.03.00)	
International application No. PCT/EP99/05405	Applicant's or agent's file reference B 2286 PCT
International filing date (day/month/year) 28 July 1999 (28.07.99)	Priority date (day/month/year) 29 July 1998 (29.07.98)
Applicant PIGNOT, Marc et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

21 February 2000 (21.02.00)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer F. Baechler Telephone No.: (41-22) 338.83.38
---	---



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07H 19/167, C12Q 1/68	A1	(11) International Publication Number: WO 00/06587 (43) International Publication Date: 10 February 2000 (10.02.00)
<p>(21) International Application Number: PCT/EP99/05405</p> <p>(22) International Filing Date: 28 July 1999 (28.07.99)</p> <p>(30) Priority Data: 98114201.1 29 July 1998 (29.07.98) EP</p> <p>(71) Applicant (for all designated States except US): MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. [DE/DE]; Berlin (DE).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): PIGNOT, Marc [DE/DE]; Brahmsstrasse 8, D-65812 Bad Soden (DE). WEINHOLD, Elmar [DE/DE]; Zwickauer Strasse 4, D-44139 Dortmund (DE).</p> <p>(74) Agent: VOSSIUS & PARTNER; Siebertstrasse 4, D-81675 München (DE).</p>		<p>(81) Designated States: CA, JP, LT, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: NEW COFACTORS FOR METHYLTRANSFERASES</p> <div data-bbox="544 1144 1055 1354"><p>(1)</p></div> <p>(57) Abstract</p> <p>Aziridine derivatives of formula (I) are disclosed which can be used as cofactor for S-adenosyl-L-methionine-dependent methyltransferases.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

New cofactors for methyltransferases

The present invention refers to aziridine derivatives which can be used as cofactors for methyltransferases, complexes and compositions containing these compounds and their use for modifying a target molecule.

Nonradioactively labeled nucleic acids are of considerable interest in molecular biology, because they can be used in DNA sequencing and can serve as probes for Southern/Northern blots, *in situ* hybridizations and colony/plaque screenings without the potential health hazards of radioactive material. Several methods are presently known in the art of covalently modifying DNA and RNA (reviewed by C. Kessler in *Nonisotopic DNA Probe Techniques*, L. J. Kricka (Ed.), Academic Press, San Diego, 1992, pp. 29-92). For instance, modified oligonucleotides can be obtained by solid-phase DNA or RNA synthesis and the so modified oligodeoxynucleotides can be used as primers for a DNA polymerase (P. Richterich, G. M. Church, *Methods Enzym.* 1993, 218, 187-222). If the modification can not withstand the reaction conditions used in the solid-phase synthesis, incorporation of amine or thiol groups and postsynthetical labeling of the obtained oligonucleotides with amine or thiol reactive probes is possible (D. M. Jameson, W. H. Sawyer, *Methods Enzym.* 1995, 246, 283-300). In addition, several labels may be coupled to terminal phosphate or thiophosphate residues in oligonucleotides (J.-L. Mergny et al., *Nucleic Acids Res.* 1994, 22, 920-928).

Another method described in the art is the incorporation of modified deoxynucleosidetriphosphates into DNA with DNA polymerases (A. Waggoner, *Methods Enzym.* 1995, 246, 362-373) or with terminal deoxynucleotidyl transferase (L. K. Riley, M. E. Marshall, M. S. Coleman, *DNA* 1986, 5, 333-338; G. L. Trainor, M. A. Jensen, *Nucleic Acids Res.* 1988, 16, 11846).

Furthermore, several modifications may be incorporated directly in DNA or RNA. For example, cytosine residues can be modified by activation with bisulfite followed by coupling with aliphatic amines (R. P. Viscidi, *Methods Enzym.* 1990, 184, 600-607; D. E. Draper, L. Gold, *Biochemistry* 1980, 19, 1774-1781). In addition, other chemical reagents for labeling DNA and RNA are commercially available (FastTag, Vector, Burlingame, CA; Mirus Label IT, Pan Vera Corporation,

Madison, WI). These later methods, however, do not result in quantitative and sequence specific modifications and thus complex mixtures are obtained.


Nonradioactive labeling of proteins is straightforward, because their cysteine and lysine residues react readily with a large variety of labeling reagents (M. Brinkley, *Bioconjugate Chem.* 1992, 3, 2-13; R. P. Haugland, *Handbook of Fluorescent Probes and Research Chemicals* 1996, Molecular Probes Inc., Eugene, OR). However, generally proteins contain many lysine or cysteine residues and labeling often results in complex mixtures which are difficult to analyze. Thus, the specific modification of proteins is even more difficult than that of DNA and RNA. One strategy to obtain specifically labeled proteins is to engineer a protein with a single cysteine residue by means of a mutagenesis; subsequently, this cysteine residue is modified for example with a fluorescent group (G. Haran, E. Haas, B. K. Szpikowska, M. T. Mas, *Proc. Natl. Acad. Sci. USA* 1992, 89, 11764-11768).

Furthermore, unnatural amino acids may be incorporated into proteins by *in vitro* translation (V. W. Cornish, D. Mendel, P. G. Schultz, *Angew. Chem.* 1995, 107, 677-690; *Angew. Chem. Int. Ed. Engl.* 1995, 34, 620-630). However, this method cannot easily be carried out and it results in only a small amount of modified protein.

Another possibility is the preparation of modified proteins by chemical peptide synthesis (T. W. Muir, S. B. H. Kent, *Current Opinion in Biotechnology* 1993, 4, 420-427); however, it is generally restricted to the preparation of relatively short protein chains.

It is the object of the present application to overcome the drawbacks of the known methods and to provide novel compounds which enable modification of biomolecules (for instance labeling) in a simple and effective way by the use of a methyltransferase.

This object is achieved by aziridine derivatives represented by formula (I)



wherein X is N or CH, Y is N or $-\text{CR}^3$, R^1 and R^3 independently from each other are H, ^3H , $-\text{NH}(\text{CH}_2)_n\text{NHR}^4$ or $-\text{NH}(\text{C}_2\text{H}_5\text{O})_n\text{C}_2\text{H}_5\text{NHR}^4$, with R^4 being selected from fluorophores, affinity tags, crosslinking agents, chromophores, proteins, peptides, amino acids which may optionally be modified, nucleotides, nucleosides, nucleic acids, carbohydrates, lipids, PEG, transfection reagents, beads and intercalating agents and n being an integer from 1-5000, and R^2 is selected from H, ^3H , $-\text{N}(\text{CH}_2)_n\text{NHR}^4$, $-\text{NH}(\text{C}_2\text{H}_5\text{O})_n\text{C}_2\text{H}_5\text{NHR}^4$ wherein R^4 and n are as defined above, $-\text{CH}_2\text{CH}(\text{COOH})(\text{NH}_2)$ or an electron-withdrawing group.

Figure 1 shows the anion exchange chromatography of the enzyme reaction with *M·TaqI* of Example 1 after different incubation times.

Figure 2A shows the RP-HPLC/ESI mass spectrum of the product duplex oligodeoxynucleotide 5-4 of Example 1 eluted after 14.6 min.

Figure 2B shows the ESI mass spectrum of the product 5-4 of Example 1 obtained by direct infusion.

Figure 3 shows the anion exchange chromatography of the enzyme reaction with *M·HhaI* of Example 1 after different incubation times.

Figure 4 shows the RP-HPLC/ESI mass spectrum of the product duplex oligodeoxynucleotide 8-7 of Example 1.

Figure 5 shows the anion exchange chromatography (UV- and fluorescence detection) of the enzyme reaction with *M·TaqI* of Example 2.

Figure 6 shows the chromatogram of labeled plasmid DNA (Example 2, labeling 3.1 with *M·TaqI*) of the anion exchange chromatography after different incubation times (6A: UV detection at 260 nm; 6B: fluorescence detection).

Figure 7 shows the chromatograms (7A: UV detection at 260 nm; 7B: fluorescence detection) obtained for non-labeled pUC19 (Example 2, labeling 3.1 without *M·TaqI*) for comparison reasons.


Figure 8 shows the chromatograms (8A: UV detection at 260 nm; 8B: fluorescence detection) of labeled and non-labeled pUC19 (Example 2, labeling 3.2 with and without *M·HhaI*);

The present invention will now be described in more detail.

S-Adenosyl-L-methionine-dependent methyltransferases (SAM-dependent methyltransferases) are a biologically important class of enzymes. They represent about 3% of the enzymes listed in the latest version of *Enzyme Nomenclature*, E. C. Webb, Academic Press, San Diego, 1992. They catalyze the transfer of the activated methyl group from the cofactor S-adenosyl-L-methionine to sulfur, nitrogen, oxygen and carbon nucleophiles of small molecules, phospholipids, proteins, RNA and DNA. For instance, DNA methyltransferases catalyze the methylation of the N6 position of adenine and the C5 or N4 position of cytosine within specific DNA sequences. Since restriction endonucleases are sensitive to DNA methylation, DNA methyltransferases can be used to decrease the number of restriction sites in DNA (M. Nelson, I. Schildkraut, *Methods Enzymol.* 1987, 155, 41-48).


The reaction known to be catalyzed by SAM-dependent methyltransferases is shown schematically in the Reaction Scheme 1, where compound 1 is the cofactor S-adenosyl-L-methionine (SAM).

Reaction Scheme 1



The inventors of the present application have now found that the aziridine derivatives of Formula I below serve as cofactors for SAM-dependent methyltransferases and by this way enable the transfer of groups larger than methyl.

The aziridine derivatives of the present invention are represented by Formula (I)



wherein X is N or CH, Y is N or $-\text{CR}^3$, R^1 and R^3 independently from each other are H, ^3H , $-\text{NH}(\text{CH}_2)_n\text{NHR}^4$ or $-\text{NH}(\text{C}_2\text{H}_5\text{O})_n\text{C}_2\text{H}_5\text{NHR}^4$, with R^4 being selected from fluorophores, affinity tags, crosslinking agents, chromophores, proteins, peptides, amino acids which may optionally be modified, nucleotides, nucleosides, nucleic acids, carbohydrates, lipids, PEG, transfection reagents, beads and intercalating agents and n being an integer from 1-5000, and R^2 is selected from H, ^3H , $-\text{N}(\text{CH}_2)_n\text{NHR}^4$, $-\text{NH}(\text{C}_2\text{H}_5\text{O})_n\text{C}_2\text{H}_5\text{NHR}^4$ wherein R^4 and n are as defined above, $-\text{CH}_2\text{CH}(\text{COOH})(\text{NH}_2)$ or an electron-withdrawing group.

Preferred electron-withdrawing groups are $-\text{CH}_{3-p}\text{R}^5_p$ (wherein $p=1, 2$ or 3 and each R^5 is independently selected from fluorine, chlorine, bromine and iodine, preferably fluorine and chlorine), $-\text{C}\equiv\text{N}$ and $-\text{C}(\text{O})\text{R}^6$ (wherein R^6 is an alkoxy group, hydroxy or an amino group which may be mono- or di-substituted with C_1 - C_{10} alkyl or C_6 - C_{10} aryl).

It is preferred that only one of R^1 , R^2 and R^3 is $-\text{NH}(\text{CH}_2)_n\text{NHR}^4$ or $-\text{NH}(\text{C}_2\text{H}_5\text{O})_n\text{C}_2\text{H}_5\text{NHR}^4$. In preferred compounds X and/or Y is N; especially preferred are compounds wherein X and Y both are N.

In the group $-\text{NH}(\text{CH}_2)_n\text{NHR}^4$ n preferably is an integer from 2 to 20, especially preferred $n = 3, 4$ or 5 .

In the group $-\text{NH}(\text{C}_2\text{H}_5\text{O})_n\text{C}_2\text{H}_5\text{NHR}^4$ n preferably is an integer from 1 to 250; more preferred n is an integer from 1 to 20.

The term fluorophore as used herein is a chemical entity in which the electrons can be excited with light of a certain energy and photons with lower energy are emitted afterwards.

In preferred compounds of the present invention R^1 and R^2 are each H or ^3H and X is N.


If at least one of R^1 , R^2 and R^3 is $-\text{NH}(\text{CH}_2)_n\text{NHR}^4$ or $-\text{NH}(\text{C}_2\text{H}_5\text{O})_n\text{C}_2\text{H}_5\text{NHR}^4$, R^4 is selected from fluorophores, affinity tags, cross-linking agents, chromophores, proteins (including antibodies and enzymes), peptides, amino acids, modified amino acids, nucleotides, nucleosides, nucleic acids, carbohydrates, lipids, PEG, transfection reagents (including polyethyleneimine, macromolecules, dendrimers), beads (e.g. those consisting of agarose, silica, nitrocellulose, cellulose, acrylamide, latex, polystyrene, polyacrylate, polymethacrylate, polyethylene polymers, glass particles, silicates, metal oxides or combinations thereof), intercalating agents (including ethidium bromide, psoralene and derivatives thereof). Preferred fluorophores are BODIPY, coumarin, dansyl, fluorescein, mansyl, pyrene, rhodamine, Texas red, TNS and cyanine fluorophores like Cy2, Cy3, Cy3.5, Cy5, Cy5.5 and Cy7; derivatives of these fluorophores can also be used. An especially preferred value for R^4 is dansyl.

If R^4 is an affinity tag, it is preferably a peptide tag, biotin, digoxigenin or dinitrophenol; useful peptide tags are for example his-tag or any tag with metal chelating properties which can be used in IMAC (Immobilized Metal Affinity Chromatography), strep-tag, flag-tag, c-myc-tag, epitopes, or glutathione.

Useful crosslinking agents are for example maleimide, iodacetamide, derivatives thereof, aldehyde derivatives and photocrosslinking agents. Examples for photocrosslinking agents are arylazide, diazo-compounds and benzophenone compounds.


N-Adenosylaziridine (compound 2) can for instance be synthesized in a one-step reaction by nucleophilic substitution of the tosylate group of 5'-tosyladenosine with aziridine (see Reaction Scheme 2 below).

Reaction Scheme 2



Reaction Scheme 3 shows the reaction catalyzed by a methyltransferase (MTase) using the natural cofactor 1 and on the other hand using the new cofactor 2 according to the present invention.


Reaction Scheme 3



In Reaction Scheme 4, lower, the modification of a short duplex oligodeoxynucleotide (3·4), consisting of a plus strand oligodeoxynucleotide (5'-GCCGCTCGATGCCG-3', 3) and a complementary minus strand oligodeoxynucleotide (5'-CGGCATCGA^{Me}GCGGC-3', 4) with the protonated cofactor analogue 2 containing aziridine by the use of the adenine-specific DNA methyltransferase from *Thermus aquaticus* (M·TaqI) is shown. The complementary minus strand oligodeoxynucleotide 4 was chosen to contain N6-methyladenine-1-β-D-2'-deoxynucleoside (A^{Me}), which can not be further methylated by M·TaqI. M·TaqI usually catalyzes the methyl group transfer from the natural cofactor 1 to the exocyclic amino group of adenine within the double-stranded 5'-TCGA-3' DNA sequence (Scheme 4, upper) (M. McClelland, *Nucleic Acids Res.* 1981, 9, 6795-6804).

The structure of the reaction product 5·4 can for instance be verified by reversed phase HPLC-coupled electrospray ionization mass spectrometry (RP-HPLC/ESI-MS).


Reaction Scheme 4



Experimental results prove that with the unnatural cofactor 2 the non-methylated plus strand 3, which contains an adenine at the target position within the 5'-TCGA-3' recognition sequence of *M·TaqI*, is modified quantitatively. Our observation that strand 4, which contains N6-methyladenine at the other target position and an adenine outside the recognition sequence, is not modified, demonstrates that the sequence specificity of *M·TaqI* is not altered with the new cofactor 2. In addition, enzymatic fragmentation of the product duplex 5-4 followed by reversed-phase HPLC analysis yielded an additional compound besides the natural nucleosides dC, dA, dG, T, and dAMe. This additional compound was isolated and detected as positively charged ion at m/z 544.6 by electrospray ionization mass spectrometry. The observed mass is identical with the calculated molecular mass of a protonated, with N-adenosylaziridine modified 2'-deoxyadenosine. This result demonstrates that only the target adenine in the plus strand 3 is modified. Thus, the *M·TaqI*-catalyzed coupling of the new cofactor 2 with DNA is quantitative, sequence- and base-specific.

The present invention, however, is not restricted to *M·TaqI* but the C5-cytosine-specific DNA methyltransferase *Haemophilus haemolyticus* (*M·HhaI*) and other methyltransferases normally using S-adenosyl-L-methionine (SAM) as cofactor can also be used. This is readily demonstrated by the modification of the duplex oligodeoxynucleotide 6-7 using *M·HhaI*. Naturally, *M·HhaI* catalyzes the transfer of the activated methyl from SAM to the carbon atom at the 5 position of the first cytosine within the double stranded 5'-GCGC-3' DNA sequence (Scheme 5, upper). Experimental results prove that *M·HhaI* also accepts the new cofactor 2 and catalyzes its coupling to the duplex oligodeoxynucleotide 6-7 (Scheme 5, lower). Like the *M·TaqI*-catalyzed reaction, the *M·HhaI*-catalyzed coupling is quantitative.


Reaction Scheme 5



This application for the first time describes the transfer of a group larger than a methyl group catalyzed by two different S-adenosyl-L-methionine-dependent methyltransferase. Since the transfer of for instance compound 2 introduces a unique secondary amino group into DNA, subsequent labeling reactions with amine reactive probes should be feasible. Thus, site-specific introduction of fluorescent, chemiluminescent or other reporter groups is possible.


Alternatively, the new fluorescent cofactor 9 where R^1 is $-NH(CH_2)_4NHR^4$, R^2 is H, Y is N and R^4 is the fluorescent dansyl group can be used to obtain sequence-specifically labeled DNA directly. This fluorescent N-adenosylaziridine derivative contains the reactive aziridine group at the 5' position, the adenosyl moiety, which serves as the molecular anchor for the cofactor binding of methyltransferases, and the fluorescent dansyl group (label), which is attached to the 8 position via a flexible linker. The synthesis of this new fluorescent cofactor 9 is illustrated in Scheme 6. Reaction of 8-bromo-2',3'-O-isopropylidene adenosine with 1,4-diaminobutane yields the protected adenosine derivative 10 with an aminolinker at the 8 position. Transient protection of the 5' hydroxy group with trimethylchlorosilan, coupling of dansyl chloride with the primary amine and removal of the 5' hydroxyl protecting group leads to the protected fluorescent adenosine derivative 11. Reaction of 11 with mesylchloride yields the mesylate 12. Removal of the isopropylidene group of 12 under acidic conditions leads to the fluorescent adenosine derivative 13 which is reacted with aziridine to give the new fluorescent cofactor 9.

Reaction Scheme 6



The M-*TaqI*-catalyzed coupling of the new fluorescent cofactor 9 with the duplex oligodeoxynucleotide 3·4 (Scheme 7) was followed by anion exchange chromatography. After proteolytic fragmentation of the formed M-*TaqI*-DNA complex the fluorescently labeled duplex oligodeoxynucleotide 14·4 is formed. The structure of the product 14·4 was verified by enzymatic fragmentation followed by reversed-phase HPLC. The analysis revealed besides the natural nucleosides dC, dA, dG, T, and dA^{Me} an additional fluorescent compound, which eluted with a much higher retention time than the natural nucleosides demonstrating its hydrophobic nature. This additional fluorescent compound was isolated and detected as positively charged ion at m/z 863.1 by electrospray ionization mass spectrometry. The observed mass is in good agreement with the calculated molecular mass of 863.4 for a protonated, with 9 modified 2'-deoxyadenosine. Thus, the coupling reaction of the new fluorescent cofactor 9 with DNA catalyzed by M-*TaqI* is quantitative and base-specific.

Reaction Scheme 7



The present invention can also be used to label larger DNA molecules. This is proved by labeling of the plasmid pUC19 (2,686 base pairs) with the new fluorescent cofactor 9 and M·*TaqI*. The labeling reaction was analyzed by anion exchange chromatography after different incubation times. While the chromatograms using UV detection did not significantly change, the chromatograms using fluorescence detection clearly showed an increase of the fluorescence signal with the incubation time. The UV signal and the fluorescence signal superimpose and indicate that the starting material pUC19 (UV absorption only) and fluorescently labeled pUC19 (UV absorption and fluorescence) elute with the same retention time. In a parallel control experiment without M·*TaqI* no fluorescence signal corresponding to fluorescently labeled pUC19 was observed. This result demonstrates that the labeling reaction is in fact M·*TaqI*-catalyzed. Interestingly, the fluorescent nucleoside 9 also function as a cofactor for M·*HhaI*. Analysis of the M·*HhaI*-catalyzed coupling reaction between fluorescent nucleoside 9 and pUC19 by anion exchange chromatography shows that fluorescently labeled pUC19 is also produced and that no labeling occurs without M·*HhaI*.

The three-dimensional structures of several methyltransferases in complex with the natural cofactor (N6-adenine DNA methyltransferase M·*TaqI*: J. Labahn, J. Granzin, G. Schluckebier, D. P. Robinson, W. E. Jack, I. Schildkraut, W. Saenger, *Proc. Natl. Acad. Sci. USA* 1994, 91, 10957-10961; N6-adenine DNA methyltransferase DpnM: P. H. Tran, Z. R. Korszun, S. Cerritelli, S. S. Springhorn, S. A. Lacks, *Structure* 1998, 6, 1563-1575; C5-cytosine DNA methyltransferase M·*HhaI*: S. Klimasauskas, S. Kumar, R. J. Roberts, X. Cheng, *Cell* 1994, 76, 357-369; N4-cytosine DNA methyltransferase M·*PvuII*: W. Gong, M. O'Gara, R. M. Blumenthal, X. Cheng, *Nucleic Acids Res.* 1997, 25, 2702-2715; N6-adenine RNA methyltransferase ErmC': D. E. Bussiere, S. W. Muchmore, C. G. Dealwis, G. Schluckebier, V. L. Nienaber, R. P. Edalji, K. A. Walter, U. S. Lador, T. F. Holzman, C. Abad-Zapatero, *Biochemistry* 1998, 37, 7103-7112; mRNA 2'-O-nucleoside methyltransferase VP39: A. E. Hodel, P. D. Gershorn, X. Shi, F. A. Quiocho, *Cell* 1996, 85, 247-256; protein methyltransferase CheR: S. Djordjevic, A. M. Stock, *Structure* 1997, 5, 545-558) indicate that the 8 position of the adenine ring of the natural cofactor is at least partly accessible to the solvent, and thus is suitable for the attachment of an additional group without strongly interfering with the cofactor binding of these methyltransferases. In some methyltransferases the 7 position of the adenine ring of the natural cofactor is even more exposed to the solvent and, therefore, might be the preferred position of choice for the attachment of additional groups (Y in Formula I) for these methyltransferases. In addition, the

three-dimensional structure of the catechol O-methyltransferase COMT in complex with the natural cofactor (J. Vidgren, L. A. Svensson, A. Liljas, *Nature* 1994, 368, 354-358) shows that the adenine ring of the natural cofactor is buried within the cofactor binding pocket. Here, the attachment of an additional group at the 5' aziridine ring (R^2 in Formula I) seems most compatible with the cofactor binding of this methyltransferase. Thus, the new cofactors with modifications at the 8-position of the adenine ring (R^1 in Formula I), at the 7 position of the adenine ring (Y in Formula I) or at the 5' aziridine ring (R^2 in Formula I) can be used to obtain a wide variety of site-specifically labeled biomolecules.

The methyltransferases useful in the present invention normally transfer the methyl group of SAM onto a nucleic acid molecule like DNA or RNA, onto a polypeptide, a protein, an enzyme or a small molecule. An overview on SAM-dependent methyltransferases is for instance given by R. M. Kagan and S. Clarke in *Archives of Biochemistry and Biophysics* 1994, 310, 417-427. This article also gives a list of small molecule O-methyltransferases and small molecule N-methyltransferases which include for example catechol O-methyltransferase and glycine N-methyltransferase.

Particularly preferred for use in the present invention are methyltransferases which methylate DNA, especially, those which are part of a restriction modification system of a bacterium and methyltransferases which methylate proteins at distinct amino acids.

The present invention not only refers to the aziridine derivatives themselves but also to the complex of such a derivative and a methyltransferase as well as pharmaceutical and diagnostic compositions comprising an aziridine derivative of the present invention or a complex thereof with a methyltransferase.

The aziridine derivatives of the present invention can be used for modifying a target molecule (e.g. DNA or fragments thereof, RNA or fragments thereof, hybrids of DNA and RNA, polypeptides, for instance proteins of fusion proteins comprising a methylation site, synthetic polymers and small molecules like lipids). This can be done by transferring an aziridine derivative of the present invention or a part thereof onto the target molecule by means of a methyltransferase.

The present invention will now be further illustrated by the following examples.

Example 1

1. Synthesis of N-adenosylaziridine, compound 2 (Scheme 2).

Dry aziridine (S. Gabriel, *Chem. Ber.* 1888, 21, 2664-2669; S. Gabriel, R. Stelzner, *Chem. Ber.* 1895, 28, 2929-2938) (360 μ l, 7.2 mmol) was added slowly to a suspension of 5'-tosyladenosine (100 mg, 0.24 mmol, Aldrich) in N-ethyldiisopropylamine (125 μ l, 0.7 mmol) under an argon atmosphere, and the resulting solution was stirred at room temperature for three days. Any aziridine remaining was removed under reduced pressure, and the crude reaction product was dissolved in water (1 ml) and neutralized with acetic acid (1 M). The solution (100 μ l at a time) was injected onto a reversed-phase HPLC column (Hypersil-ODS, 5 μ m, 120 Å, 250 x 10 mm, Bischoff, Leonberg, Germany), and the product was eluted with a linear gradient of acetonitrile (7–10% in 30 min, 2 ml/min) in triethylammonium hydrogencarbonate buffer (0.1 M, pH 8.4). Fractions containing product (retention time 11.3 min, UV detection at 259 nm) were combined, concentrated by lyophilization to 5.5 ml (10.5 mM, using $\lambda = 260$, $\epsilon = 15400$ of adenosine) and stored at -80°C . Yield: 0.058 mmol (24%). For further characterization an aliquot was completely lyophilized to afford compound 2 as a white solid.

^1H NMR (500 MHz, D_2O): $\delta = 1.49\text{--}1.40$ (m, 2H; aziridine-H), 1.85–1.74 (m, 2H; aziridine-H), 2.74 and 2.68 (AB part of ABX-spectrum, $^3J = 4.3, 6.6$ Hz, $2J = 13.3$ Hz, 2H; 5'- H_a , 5'- H_b), 4.35 (ddd = dt, $^3J = 4.6, 4.6, 6.7$ Hz, 1H; 4'-H), 4.46 (dd = t, $^3J = 5.1$ Hz, 1H; 3'-H), 4.84 (dd = t, $^3J = 5.3$ Hz, 1H; 2'-H), 6.13 (d, $^3J = 5.0$ Hz, 1H; 1'-H), 8.30 (s, 1H; 8-H), 8.36 (s, 1H; 2-H).

FAB-MS (thioglycolic acid): m/z (%): 293 (100) [$M^+ + \text{H}$], 250 (4) [$M^+ - \text{C}_2\text{H}_4\text{N}$], 178 (11) [$\text{B}^+ + \text{C}_2\text{H}_4\text{O}$], 167 (34), 165 (5), 164 (5) [$\text{B}^+ + \text{CH}_2\text{O}$], 158 (36) [$M^+ - \text{B}$], 149 (78), 136 (91) [BH_2^+], 102 (23); B = deprotonated adenine.

2. Synthesis and purification of oligodeoxynucleotides.

Oligodeoxynucleotides 3, 4, 6 and 7 were synthesized on an Applied Biosystems 392 DNA/RNA synthesizer, using standard β -cyanoethyl phosphoramidite chemistry. Syntheses were performed "trityl on" and oligodeoxynucleotides were purified by reversed-phase HPLC. After

detritylation with acetic acid (80%), the oligodeoxynucleotides were further purified by reversed-phase HPLC ("trityl off") and desalted by gel filtration. The duplex oligodeoxynucleotides 3-4 and 6-7 were formed by incubating equal molar amounts of the complementary strands in buffer (20 mM Tris acetate, 50 mM potassium acetate, 10 mM magnesium acetate, pH 7.9 for 3-4 and 10 mM Tris chloride, 50 mM sodium chloride, 0.5 mM EDTA, pH 7.4 for 6-7) at 95°C (2 min) followed by slow cooling (2 h) to room temperature.

3. Enzyme reactions

3.1 Enzyme reaction with the N6-adenine DNA methyltransferase M·TaqI.

The DNA methyltransferase M·TaqI free of cofactor was prepared as described before (B. Holz, S. Klimasauskas, S. Serva, E. Weinhold, *Nucleic Acids Res.* 1998, 26, 1076-1083). The enzyme-catalyzed reaction was carried out in a mixture (500 µl) of M·TaqI (5 nmol, 10 µM), duplex oligodeoxynucleotide 3-4 (5 nmol, 10 µM), compound 2 (500 nmol, 1 mM), Tris acetate (20 mM, pH 6.0), potassium acetate (50 mM), magnesium acetate (10 mM) and Triton X-100 (0.01%) at 37°C. The progress of the reaction was monitored by anion exchange chromatography. Aliquots (50 µl) of the reaction mixture were withdrawn after different incubation times, mixed with an urea solution (100 µl, 6 M) and injected onto an anion exchange column (Poros 10 HQ, 10 µm, 4.6 x 100 mm, PerSeptive Biosystems, Germany). Compounds were eluted with aqueous potassium chloride (0.5 M for 5 min, followed by a linear gradient to 1 M in 30 min, 4 ml/min) in Tris chloride buffer (10 mM, pH 7.6). The chromatograms of the anion exchange chromatography after different incubation times are shown in Figure 1.

Analysis of the product duplex oligodeoxynucleotide 5-4 by reversed-phase HPLC-coupled electrospray ionization mass spectrometry: RP-HPLC/ESI-MS was performed with an ion-trap mass spectrometer (LCQ, Finnigan MAT, Germany) equipped with a micro HPLC system (M480 and M300, Gynkotek, Germany). The product duplex oligodeoxynucleotide 5-4 was purified by anion exchange chromatography (see above) and desalted by repeated addition of water and ultrafiltration (Microsep 3K, Pall Filtron, Northborough, MA, USA). A solution of purified and desalted 5-4 was injected onto a capillary column (Hypersil-ODS, 3 µm, 150 x 0.3 mm, LC Packings, Amsterdam, Netherlands) and eluted with a linear gradient of acetonitrile (7–

10% in 10 min, followed by 10–70% in 30 min, 150 μ l/min) in triethylammonium acetate buffer (0.1 M, pH 7.0). The RP-HPLC/ESI mass spectra shown in Figure 2A was obtained in the negative ion mode using standard conditions. The chromatogram obtained by observing the total ion current is given in the inset of Figure 2A.

Analysis of the product duplex oligodeoxynucleotide 5-4 by electrospray ionization mass spectrometry using direct infusion: The ESI mass spectrum shown in Figure 2B was acquired using a double focussing sector field mass spectrometer MAT 90 (Finnigan MAT, Germany) equipped with an ESI II electrospray ion source in the negative ion mode. Desalted 5-4 (aqueous solution) and a liquid sheath flow (2-propanol) were delivered using a Harvard syringe pump (Harvard Apparatus, USA). The inset in Figure 2B shows an expansion of the signal for the $[5-6H]^{6-}$ ion with isotopic resolution.

The molecular weights of oligodeoxynucleotides observed in the electrospray mass spectra from Figure 2A and 2B are summarized in Table 1. In addition, the observed molecular weights of the educt oligodeoxynucleotides are given.

Table 1

Compound	Charge	(m/z) _{expt}	M_{expt}	M_{calcd}
1) RP-HPLC/ESI-MS				
5-4	5 –	1766.5	8837.5	8836.9
5	3 –	1510.1	4533.3	4533.1
4	3 –	1433.9	4304.7	4303.8
3-4	5 –	1708.0	8545.0	8544.6
3	3 –	1412.7	4241.1	4240.8
2) ESI-MS by direct infusion				
5	6 –	754.5	4533.1	4533.1
4	6 –	716.1	4302.7	4303.8
3	6 –	705.7	4240.3	4240.8

Analysis of the product duplex oligodeoxynucleotide 5-4 by enzymatic fragmentation: Purified and desalted 5-4 (0.25 OD at 260 nm) was dissolved in potassium phosphate buffer (10 mM, pH 7.0, 100 μ l) containing magnesium chloride (10 mM), DNase I (1.2 U), phosphodiesterase from

Crotalus durissus (0.018 U), phosphodiesterase from calf spleen (0.024 U) and alkaline phosphatase (6 U) and incubated at 37°C for 24 h. An aliquot (50 µl) was injected onto a reversed-phase HPLC column (Hypersil-ODS, 5 µm, 120 Å, 250 x 4.6 mm, Bischoff, Leonberg, Germany), and the products were eluted with a linear gradient of acetonitrile (0–10.5% in 30 min, 1 ml/min) in triethylammonium acetate buffer (0.1 M, pH 7.0). The RP-HPLC analysis of the digest revealed besides dC, dA, dG, T, and dA^{Me} an additional compound eluting between T and dA^{Me}. This additional compound was isolated and detected as positively charged ion at m/z 544.6 by ESI-MS (LCQ connected to a nanoelectrospray ion source, Finnigan MAT, Germany). The observed mass is identical with the calculated molecular mass of a protonated, with N-adenosylaziridine modified 2'-deoxyadenosine.

3.2 Enzyme reaction with the C5-cytosine DNA methyltransferase M·HhaI.

The DNA methyltransferase M·HhaI free of cofactor was prepared as described before (B. Holz, S. Klimasauskas, S. Serva, E. Weinhold, *Nucleic Acids Res.* 1998, 26, 1076-1083). The enzyme-catalyzed reaction was carried out in a mixture (500 µl) of M·HhaI (5 nmol, 10 µM), duplex oligodeoxynucleotide 6·7 (5 nmol, 10 µM), compound 2 (500 nmol, 1 mM), Tris chloride (10 mM, pH 7.4), sodium chloride (50 mM), EDTA (0,5 mM) and Triton X-100 (0.01%) at 25°C. The progress of the reaction was monitored by anion exchange chromatography. Aliquots (50 µl) of the reaction mixture were withdrawn after different incubation times, and injected onto an anion exchange column (Poros 10 HQ, 10 µm, 4.6 x 100 mm, PerSeptive Biosystems, Germany). Compounds were eluted with aqueous potassium chloride (0 M for 5 min, followed by a linear gradient to 0.5 M in 5 min and to 1 M in 30 min, 4 ml/min) in Tris chloride buffer (20 mM, pH 7.6). The chromatograms of the anion exchange chromatography after different incubation times are shown in Figure 3.

Analysis of the product duplex oligodeoxynucleotide 8·7 by reversed-phase HPLC-coupled electrospray ionization mass spectrometry: RP-HPLC/ESI-MS was performed as described before for the analysis of 5·4 (see example 1, 3.1). The obtained RP-HPLC/ESI mass spectrum is shown in Figure 4 and the observed molecular weights of oligodeoxynucleotides are summarized in Table 2.

Table 2

Compound	Charge	(<i>m/z</i>) _{expt}	<i>M</i> _{expt}	<i>M</i> _{calcd}
8·7	3 –	2738.4	8220.2	8215.5
8·7	4 –	2054.1	8220.4	8215.5
8·7	5 –	1642.8	8219.0	8215.5

Analysis of the product duplex oligodeoxynucleotide 8·7 by enzymatic fragmentation: Enzymatic fragmentation of 8·7 was performed as described before for 5·4 (see example 1, 3.1). The RP-HPLC analysis of the digest revealed besides dC, dCMe, dA, dG, T an additional compound eluting before dC.

Example 2

1. Synthesis of a fluorescent N-adenosylaziridine derivative, compound 9 (Scheme 6).
- 1.1 8-Amino[1''-(4''-aminobutyl)]-2',3'-O-isopropylidene adenosine, compound 10.

To a solution of 8-bromo-2',3'-O-isopropylene adenosine (M. Ikehara, H. Tada, M. Kaneko, *Tetrahedron* 1968, 24, 3489-3498) (628 mg, 1.6 mmol) in dry DMSO (10 ml) under an argon atmosphere, dry triethylamine (2.26 ml, 16.3 mmol) and 1,4-diaminobutane (0.82 ml, 8.1 mmol) were added. The solution was stirred at 110°C and the reaction progress monitored by TLC. After 4 h the solvent was removed under reduced pressure. The residue was dissolved in water (50 ml) and the pH was adjusted to 5.3 with acetic acid (0.1 M). The crude product was purified by cation exchange chromatography (Dowex 50 x 4 in H⁺-form, 100 g, elution with 600 ml water and subsequently with 1000 ml 1 M potassium hydroxide). Fractions containing the product were extracted with chloroform, and the solvent was removed under reduced pressure. Yield: 639 mg (100%).

$R_f = 0.44$ (butanol/acetic acid/water 3:0.75:1.25).

¹H NMR (500 MHz, CDCl₃): δ = 1.33 (s, 3H; acetone-H), 1.48–1.55 (m, 2H; linker-H), 1.61 (s, 3H; acetone-H), 1.64–1.70 (m, 2H; linker-H), 2.66–2.73

(m, 2H; linker-H), 3.33–3.42 (m, 2H; linker-H), 3.77–3.91 (m, 2H; 5'-H), 4.28–4.30 (m, 1H; 4'-H), 4.99 (dd, $^3J = 2.7, 6.3$ Hz, 1H; 3'-H), 5.08 (dd, $^3J = 4.8, 6.3$ Hz, 1H; 2'-H), 5.39 (s, br., 2H; 6-NH₂), 6.15 (d, $^3J = 4.5$ Hz, 1H; 1'-H), 6.55–6.60 (m, 1H; 8-NH), 8.10 (s, 1H; 2-H).

¹³C-NMR (125.7 MHz, CDCl₃): $\delta = 25.30$ (q; acetonide-CH₃), 25.73 (t; linker-C), 27.42 (q; acetonide-CH₃), 29.60 (t; linker-C), 40.46 (t; linker-C), 42.69 (t; linker-C), 61.17 (t; 5'-C), 80.59 (d; 3'-C), 82.19 (d; 2'-C), 84.48 (d; 4'-C), 89.21 (d; 1'-C), 114.50 (s; acetonide-C(CH₃)₂), 117.68 (s; 5-C), 149.49 (d; 2-C), 149.95 (s; 8-C), 151.68 (s; 4-C), 151.72 (s; 6-C).

ESI-MS: *m/z* (%): 394.3 (25) [M + H]⁺, 222.3 (100) [adenine + aminobutyl + H]⁺.

1.2 8-Amino[1''-(N''-dansyl)-4''-aminobutyl]-2',3'-O-isopropylidene adenosine, compound 11.

To a solution of 10 (104 mg, 0.26 mmol) in dry pyridine (7 ml) under an argon atmosphere, trimethylchlorosilane (0.07 ml, 0.53 mmol) was added slowly at 0°C, and the resulting solution was stirred at room temperature for 1 h. Subsequently, dansyl chloride (103.8 mg, 0.37 mmol, in 3 ml pyridine) was added and the solution was stirred at room temperature for 4 h. The progress of the reaction was monitored by TLC, and after complete conversion the solution was treated with water (5 ml) at 0°C. The solvent was removed under reduced pressure, and the crude product was purified by column chromatography (silica gel, 40 g, elution with methylene chloride/methanol 19:1). Yield: 50 mg (30%).

R_f = 0.54 (methylene chloride/methanol 9:1).

¹H-NMR (500 MHz, DMSO-d₆): $\delta = 1.29$ (s, 3H; acetonide-H), 1.39–1.43 (m, 2H; linker-H), 1.47–1.50 (m, 2H; linker-H), 1.53 (s, 3H; acetonide-H), 2.78–2.82 (m, 8H; linker-H and N(CH₃)₂), 3.16–3.24 (m, 2H; linker-H), 3.50–3.58 (m, 2H; 5'-H), 4.12–4.14 (m, 1H; 4'-H), 4.94 (dd, $^3J = 2.7, 6.1$ Hz, 1H; 3'-H), 5.33 (dd, $^3J = 3.7, 6.1$ Hz, 1H; 2'-H), 5.41–5.44 (m, 1H; 5'-OH), 6.01 (d, $^3J = 3.5$ Hz, 1H; 1'-H), 6.49 (s, br., 2H; 6-NH₂), 6.85 (t, $^3J = 5.0$ Hz, 1H; 8-NH), 7.22 (d, $^3J = 7.5$ Hz, 1H; arom.-H), 7.54–7.61 (m, 2H; arom.-H), 7.87–7.90 (m, 1H; NHSO₂), 7.90 (s, 1H; 2-H), 8.08 (d, $^3J = 7.2$ Hz, 1H; arom.-H), 8.30 (d, $^3J = 8.5$ Hz, 1H; arom.-H), 8.43 (d, $^3J = 8.5$ Hz, 1H; arom.-H).

^{13}C -NMR (125.7 MHz, DMSO-d_6): δ = 25.42 (q; acetonide- CH_3), 26.00 (t; linker-C), 26.96 (t; linker-C), 27.33 (q; acetonide- CH_3), 41.92 (t; linker-C), 42.43 (t; linker-C), 45.21 (q; $\text{N}(\text{CH}_3)_2$), 61.40 (t; 5'-C), 81.14 (d; 3'-C), 81.50 (d; 2'-C), 85.29 (d; 4'-C), 87.85 (d; 1'-C), 113.38 (s), 115.24 (d; arom.-C), 117.24 (s), 119.29 (d; arom.-C), 123.72 (d; arom.-C), 127.92 (d; arom.-C), 128.31 (d; arom.-C), 129.26 (s), 129.48 (d; arom.-C), 136.27 (s), 148.89 (d; 2-C), 149.30 (s), 151.20 (s), 151.50 (s), 152.58 (s).

ESI-MS: m/z (%): 627.1 (100) $[\text{M} + \text{H}]^+$, 455.2 (8) [adenine + linker + dansyl + $\text{H}]^+$.

1.3 8-Amino[1''-(N''-dansyl)-4''-aminobutyl]-2',3'-O-isopropylidene-5'-O-mesyl adenosine, compound 12.

To a solution of 11 (181 mg, 0.32 mmol) and dimethylaminopyridine (40 mg, 0.32 mmol) in dry methylene chloride (20 ml) under an argon atmosphere, dry triethylamine (1.1 ml, 8.0 mmol) was added and the resulting solution was cooled to 0°C . Mesylchloride (200 μl , 2.6 mmol) was added and the solution was stirred for 30 min. The reaction was quenched with a cold, saturated sodium hydrogencarbonate solution (5 ml). The solution was extracted three times with cold chloroform (10 ml). The organic phases were combined and the solvent removed under reduced pressure. The crude product was purified by column chromatography (silica gel, 40 g, elution with methylene chloride/methanol 97:3). Yield: 96 mg (43 %).

R_f = 0.55 (methylene chloride/methanol 9:1).

^1H -NMR (500 MHz, CDCl_3): δ = 1.37 (s, 3H; acetonide-H), 1.45–1.48 (m, 2H; linker-H), 1.59–1.61 (m, 5H; linker-H and acetonide-H), 2.85 (s, 6H; $\text{N}(\text{CH}_3)_2$), 2.96 (s, 3H; SO_2CH_3), 2.98–3.02 (m, 2H; linker-H), 3.32–3.36 (m, 2H; linker-H), 4.33–4.43 (m, 3H; 5'-H and 4'-H), 5.03 (dd, 3J = 9.8, 6.1 Hz, 1H; 3'-H), 5.52 (dd, 3J = 2.5, 6.5 Hz, 1H; 2'-H), 6.04 (d, 3J = 2.5 Hz, 1H; 1'-H), 6.13 (s, br., 2H; 6- NH_2), 6.91 (t, 3J = 5.8 Hz, 1H; 8-NH), 7.13 (d, 3J = 7.3 Hz, 1H; arom.-H), 7.43 (t, 3J = 8.2 Hz, 1H; arom.-H), 7.50 (t, 3J = 7.9 Hz, 1H; arom.-H), 8.10 (s, 1H; 2-H), 8.23 (d, 3J = 7.0 Hz, 1H; arom.-H), 8.37 (d, 3J = 8.5 Hz, 1H; arom.-H), 8.51 (d, 3J = 8.6 Hz, 1H; arom.-H).

^{13}C -NMR (125.7 MHz, CDCl_3): δ = 24.62 (q; acetonide- CH_3), 25.30 (t; linker-C), 26.89 (t; linker-C), 27.04 (q; acetonide- CH_3), 37.50 (q; SO_2CH_3), 41.58 (t; linker-C), 42.70 (t; linker-C), 45.44 (q; $\text{N}(\text{CH}_3)_2$), 68.38 (t; 5'-C), 80.10 (d; 3'-C), 82.11 (d; 2'-C), 83.29 (d; 4'-C), 88.63 (d; 1'-C), 115.16 (d; arom.-C), 118.94 (d; arom.-C), 123.23 (d; arom.-C), 128.20 (d; arom.-C), 129.70 (d; arom.-C), 130.37 (d; arom.-C), 149.78 (d; 2-C), 151.84 (s), 152.41 (s).

ESI-MS: m/z (%): 705.3 (70) $[\text{M} + \text{H}]^+$, 609.7 (100) [cyclonucleoside + $\text{H}]^+$.

1.4 8-Amino[1''-(N''-dansyl)-4''-aminobutyl]-5'-O-mesyl adenosine, compound 13.

Nucleoside 12 (96.2 mg, 0.14 mmol) was dissolved in aqueous formic acid (50%, 10 ml), and the resulting solution was stirred at room temperature for 4 d. After complete conversion the solvent was removed under reduced pressure and remaining solvent was coevaporated with a mixture of water and methanol (1:1, 5 ml). The crude product was purified by column chromatography (silica gel, 15 g, elution with methylene chloride/methanol 9:1). Yield: 49.2 mg (55 %).

R_f = 0.23 (methylene chloride/methanol 9:1).

^1H -NMR (500 MHz, $\text{DMSO}-d_6$): δ = 1.36–1.42 (m, 2H; linker-H), 1.47–1.53 (m, 2H; linker-H), 2.77–2.79 (m, 2H; linker-H), 2.81 (s, 6H; $\text{N}(\text{CH}_3)_2$), 3.07 (s, 3H; SO_2CH_3), 3.17–3.20 (m, 2H; linker-H), 4.01–4.04 (m, 1H; 4'-H), 4.33–4.47 (m, 3H; 5'-H and 3'-H), 5.08 (ddd = q, 3J = 5.5 Hz, 1H; 2'-H), 5.37 (d, 3J = 5.5 Hz, 1H; OH), 5.44 (d, 3J = 5.5 Hz, 1H; OH), 5.72 (d, 3J = 5.1 Hz, 1H; 1'-H), 6.48 (s, br., 2H; 6- NH_2), 6.78 (t, 3J = 5.3 Hz, 1H; 8-NH), 7.24 (d, 3J = 7.8 Hz, 1H; arom.-H), 7.57 (t, 3J = 8.3 Hz, 1H; arom.-H), 7.61 (t, 3J = 7.8 Hz, 1H; arom.-H), 7.88 (s, 1H; 2-H), 7.95 (t, 3J = 5.7 Hz, 1H; NHSO_2), 8.08 (d, 3J = 6.9 Hz, 1H; arom.-H), 8.28 (d, 3J = 8.7 Hz, 1H; arom.-H), 8.44 (d, 3J = 8.7 Hz, 1H; arom.-H).

^{13}C -NMR (125.7 MHz, $\text{DMSO}-d_6$): δ = 27.24 (t; linker-C), 28.06 (t; linker-C), 37.91 (q; SO_2CH_3), 43.07 (t; linker-C), 43.58 (t; linker-C), 46.41 (q; $\text{N}(\text{CH}_3)_2$), 71.21 (t; 5'-C), 71.45 (d; 3'-C), 71.61 (d; 2'-C), 82.20 (d; 4'-C), 88.63 (d; 1'-C), 116.44 (d; arom.-C), 118.76 (s), 120.46 (d; arom.-C), 124.98 (d; arom.-C), 129.16 (d; arom.-C), 129.54 (d; arom.-C), 130.34 (s), 130.39 (d; arom.-C), 130.68 (s), 137.35 (s), 149.95 (d; 2-C), 150.78 (s), 152.66 (s), 153.06 (s), 153.73 (s).

ESI-MS: m/z (%): 665.6 (85) $[M + H]^+$, 687.4 (100) $[M + Na]^+$.

1.5 Synthesis of 8-Amino[1''-(N''-dansyl)-4''-aminobutyl]-5'-(1-aziridiny)-5'-deoxy adenosine, compound 9

Nucleoside 13 (20 mg, 30 μ mol) was dissolved in dry aziridine (S. Gabriel, *Chem. Ber.* 1888, 21, 2664-2669; S. Gabriel, R. Stelzner, *Chem. Ber.* 1895, 28, 2929-2938) (1 ml) and N-ethyldiisopropylamine (350 μ l) under an argon atmosphere, and stirred at room temperature for 3 d. The reaction was monitored by analytical reversed-phase HPLC (Hypersil-ODS, 5 μ m, 120 Å, 250 x 4.6 mm, Bischoff, Leonberg, Germany). Compounds were eluted with acetonitrile (0% for 5 min, followed by a linear gradient to 35% in 30 min and to 70% in 10 min, 1 ml/min) in triethylammonium acetate buffer (0.1 M, pH = 7.0). The solvent was removed under reduced pressure after completeness of the reaction. The crude product was purified by column chromatography (silica gel, 2 g, elution with methylene chloride/methanol 9:1). Yield: 6.7 mg (36%).

R_f = 0.23 (methylene chloride/methanol 9:1).

$^1\text{H-NMR}$ (500 MHz, DMSO- d_6): δ = 1.19–1.22 (m, 2H; aziridine-H), 1.32–1.34 (m, 2H; linker-H), 1.37–1.39 (m, 2H; linker-H), 1.59–1.61 (m, 2H; aziridine-H), 1.94 (dd, 3J = 3.2 Hz, 2J = 13.5 Hz, 1H; 5'-H_a), 2.74–2.79 (m, 2H; linker-H), 2.81 (s, 6H; N(CH₃)₂), 2.91–2.95 (m, 1H; 5'-H_b), 3.07–3.16 (m, 2H; linker-H), 3.94–3.96 (m, 1H; 4'-H), 4.19–4.21 (m, 1H; 3'-H), 4.63–4.67 (m, 1H; 2'-H), 5.20 (d, 3J = 4.1 Hz, 1H; OH), 5.30 (d, 3J = 6.8 Hz, 1H; OH), 5.90 (d, 3J = 7.2 Hz, 1H; 1'-H), 6.42 (s, br., 2H; 6-NH₂), 7.23 (d, 3J = 7.2 Hz, 1H; arom.-H), 7.55–7.61 (m, 3H; arom.-H and 8-NH), 7.87 (s, 1H; 2-H), 7.95 (t, 3J = 5.6 Hz, 1H; NHSO₂), 8.08 (d, 3J = 7.2 Hz, 1H; arom.-H), 8.28 (d, 3J = 8.6 Hz, 1H; arom.-H), 8.43 (d, 3J = 8.6 Hz, 1H; arom.-H).

$^{13}\text{C-NMR}$ (125.7 MHz, DMSO- d_6): δ = 26.92 (t; aziridine-C), 27.43 (t; linker-C), 28.01 (t; linker-C), 30.02 (t; aziridine-C), 43.02 (t; linker-C), 43.65 (t; linker-C), 46.41 (q; N(CH₃)₂), 62.96 (t; 5'-C), 71.14 (d; 2'-C), 72.29 (d; 3'-C), 85.31 (d; 4'-C), 87.11 (d; 1'-C), 116.45 (d; arom.-C), 118.20 (s), 120.45 (d; arom.-C), 124.96 (d; arom.-C), 129.16 (d; arom.-C), 129.57 (d; arom.-C), 130.00 (s), 130.36 (d; arom.-C), 130.68 (s), 137.37 (s), 149.86 (d; 2-C), 151.49 (s), 152.42 (s), 152.66 (s), 153.43 (s).

ESI-MS: m/z (%): 612.7 (100) $[M + H]^+$.

2. Enzyme reaction with the N6-adenine DNA methyltransferase M·*TaqI*. (Scheme 7)

The enzyme-catalyzed reaction was carried out in a mixture (500 μ l) of cofactor free M·*TaqI* (5 nmol, 10 μ M), duplex oligodeoxynucleotide 3·4 (5 nmol, 10 μ M), compound 9 (10 nmol, 20 μ M), Tris acetate (20 mM, pH 6.0), potassium acetate (50 mM), magnesium acetate (10 mM) and Triton X-100 (0.01%) at 37°C. The progress of the reaction was monitored by anion exchange chromatography (Poros 10 HQ, 10 μ m, 4,6 x 10 mm, PerSeptive Biosystems, Germany). Compounds were eluted with aqueous potassium chloride (0.2 M for 5 min, followed by a linear gradient to 0.5 M in 5 min and to 1 M in 30 min) in Tris chloride buffer (10 mM, pH 7.0). Complete conversion to a new product (containing DNA and protein) with a retention time of 7.9 min was observed after 15 h. (No conversion of the duplex oligodeoxynucleotide 3·4 was observed in a parallel control experiment without M·*TaqI*.) For the fragmentation of the obtained protein–DNA complex the reaction solution was treated with a potassium hydroxide solution (10 M) to adjusted the pH to 8.0. Then, a solution (4 μ l) of proteinase K (31 mg/ml), Tris chloride (50 mM, pH 8.0) and calcium chloride (1 mM) was added, and the reaction mixture was incubated at 37°C for 1 h. The proteolytic fragmentation was monitored by anion exchange chromatography as described above. The fluorescent species with a retention time of 7.9 min disappeared and the new fluorescent compound 14·4 with a retention time of 29.2 min was formed (Figure 5). For further characterization the product 14·4 was isolated by reversed phase chromatography (column: Hypersil-ODS, 5 μ m, 120 Å, 250 x 4.6 mm, Bischoff, Leonberg, Germany; elution: triethylammonium acetate buffer, 0.1 M, pH 7.0 for 5 min, followed by a linear acetonitrile gradient to 35% in 30 min, 1 ml/min).

Analysis of the product duplex oligodeoxynucleotide 14·4 by enzymatic fragmentation: Purified 14·4 (0.57 OD at 260 nm) was dissolved in potassium phosphate buffer (10 mM, pH 7.0, 228 μ l) containing magnesium chloride (10 mM), DNase I (2.7 U), phosphodiesterase from *Crotalus durissus* (0.041 U), phosphodiesterase from calf spleen (0.055 U) and alkaline phosphatase (13.7 U) and incubated at 37°C for 20 h. An aliquot (100 μ l) was injected onto a reversed-phase HPLC column (Hypersil-ODS, 5 μ m,

120 Å, 250 x 4.6 mm, Bischoff, Leonberg, Germany), and the products were eluted with a gradient of acetonitrile (0–10.5% in 30 min followed by 10.5–28% in 10 min and 28–70% in 15 min, 1 ml/min) in triethylammonium acetate buffer (0.1 M, pH 7.0). Beside the deoxynucleosides dC, dA, dG, T, and dA^{Me} a new fluorescent compound eluting after 49 min was found. This new compound was isolated and detected as positively charged ion at m/z 863.1 by ESI-MS (LCQ connected to a nanoelectrospray ion source, Finnigan MAT, Germany). The observed mass is in good agreement with the calculated molecular mass (863.4) of a protonated, with 9 modified 2'-deoxyadenosine.

3. Fluorescent labeling

3.1 Fluorescent labeling of plasmid DNA using the N6-adenine DNA methyltransferase *M·TaqI*.

The enzyme-catalyzed labeling reaction was carried out in a mixture (500 µl) of cofactor free *M·TaqI* (133 nM), pUC19 DNA (28 nM, 4 recognition sites for *M·TaqI*), compound 9 (20 µM), Tris acetate (20 mM, pH 6,0), potassium acetate (50 mM), magnesium acetate (10 mM) and Triton X-100 (0,01%) at 65°C. The progress of the reaction was monitored by anion exchange chromatography (NUCLEOGEN DEAE 4000-7, 7 µm, 125 x 6,2 mm, Machery-Nagel, Düren, Germany). Compounds were eluted with aqueous potassium chloride (0.2 M for 5 min followed by a linear gradient to 1 M in 30 min) in Tris chloride buffer (10 mM, pH 7.0) containing acetonitrile (20%). The chromatograms of the anion exchange chromatography after different incubation times are shown in Figure 6 (A: UV detection at 260 nm; B: fluorescence detection). The delay between the observed UV absorption and the fluorescence is due to a spatial separation of the UV detector and the fluorescence detector. The labeling reaction yielding fluorescent pUC19 was completed after 8 h. No fluorescently labeled pUC19 was observed in a parallel control experiment without *M·TaqI* (Figure 7A and 7B).


3.2 Fluorescent labeling of plasmid DNA using the C5-cytosine DNA methyltransferase *M·HhaI*.

The enzyme-catalyzed labeling reaction was carried out in a mixture (100 µl) of *M·HhaI* (730 nM), pUC19 DNA (40 nM, 17 recognition sites for *M·HhaI*), compound 9 (20 µM), Tris chloride (10 mM, pH 6.85), sodium chloride (50 mM), EDTA (0,5 mM) and β-mercaptoethanol (2 mM) at 37°C. A parallel

control experiment was performed without *M·HhaI*. Aliquots of both incubations after 20 h reaction time were analyzed by anion exchange chromatography as described above (see example 2, 3.1). The obtained chromatograms are shown in Figure 8 (A: UV detection at 260 nm; B: fluorescence detection). No fluorescent labeling was observed in absence of *M·HhaI*.

Claims

1. Aziridine derivative represented by formula (I)




wherein X is N or CH, Y is N or $-\text{CR}^3$, R^1 and R^3 independently from each other are H, ^3H , $-\text{NH}(\text{CH}_2)_n\text{NHR}^4$ or $-\text{NH}(\text{C}_2\text{H}_5\text{O})_n\text{C}_2\text{H}_5\text{NHR}^4$, with R^4 being selected from fluorophores, affinity tags, crosslinking agents, chromophors, proteins, peptides, amino acids which may optionally be modified, nucleotides, nucleosides, nucleic acids, carbohydrates, lipids, PEG, transfection reagents, beads and intercalating agents and n being an integer from 1-5000, and R^2 is selected from H, ^3H , $-\text{N}(\text{CH}_2)_n\text{NHR}^4$, $-\text{NH}(\text{C}_2\text{H}_5\text{O})_n\text{C}_2\text{H}_5\text{NHR}^4$ wherein R^4 and n are as defined above, $-\text{CH}_2\text{CH}(\text{COOH})(\text{NH}_2)$ or an electron-withdrawing group.

2. Aziridine derivative of claim 1, wherein X and Y are both N.
3. Aziridine derivative of claim 1, wherein only one of R^1 , R^2 and R^3 is $-\text{NH}(\text{CH}_2)_n\text{NHR}^4$ or $-\text{NH}(\text{C}_2\text{H}_5\text{O})_n\text{C}_2\text{H}_5\text{NHR}^4$, the other(s) being H.
4. Aziridine derivative of claim 1, wherein said fluorophore is selected from BODIPY, coumarin, dansyl, fluorescein, mansyl, pyrene, rhodamine, Texas red, TNS, the cyanine fluorophores Cy2, Cy3, Cy3.5, Cy5, Cy5.5 and Cy7, and derivatives thereof.
5. Aziridine derivative of claim 1, wherein said affinity tag is a peptide tag, biotin, digoxigenin or dinitrophenol.

6. Aziridine derivative of claim 5, wherein said peptide tag is his-tag or any tag with metal chelating properties which can be used in IMAC, strep-tag, flag-tag, c-myc-tag, epitopes or glutathione.
7. Aziridine derivative of claim 1, wherein said crosslinking agent is maleimide, iodacetamide, a derivative thereof or an aldehyde derivative, or a photocrosslinking agent.
8. Aziridine derivative of claim 7, wherein said photocrosslinking agent is an arylazide, a diazo compound or a benzophenone compound.
9. A complex of the compound of any one of claims 1 to 8 and a methyltransferase which normally uses S-adenoyl-L-methionine (SAM) as a cofactor.
10. The complex of claim 9, wherein said methyltransferase normally transfers the methyl group of SAM onto a nucleic acid molecule, a polypeptide, a protein, an enzyme or a small molecule.
11. The complex of claim 10, wherein said methyltransferase methylates DNA.
12. The complex of claim 11, wherein said methyltransferase is part of a restriction modification system of a bacterium.
13. The complex of claim 10, wherein said methyltransferase methylates proteins at distinct amino acids.
14. The complex of claim 12, wherein the methyltransferase is selected from the DNA methyltransferases *M-TaqI* and *M-HhaI*.
15. A kit comprising the compound of any one of claim 1 to 8.
16. The kit of claim 15 further comprising a methyltransferase as defined in any one of claims 9 to 14.
17. A kit comprising the complex of any one of claims 9 to 14.
18. A pharmaceutical composition comprising the compound of any one of claims 1 to 8 or the complex of any one of claims 9 to 14 and optionally a pharmaceutically acceptable carrier.


19. A diagnostic composition comprising the compound of any one of claims 1 to 8 or the complex of any one of claims 9 to 14.
20. Use of the compound of any one of claims 1 to 8 for modifying a target molecule.
21. The use of claim 20, wherein the modification of the target molecule is achieved by using the compound of any one of claims 1 to 8 as a cofactor of a methyltransferase which transfers the compound or part of the compound onto the target molecule.
22. The use of claim 20 or 21, wherein the target molecule is a nucleic acid molecule, a polypeptide, a synthetic polymer or a small molecule.
23. The use of claim 22, wherein the nucleic acid molecule is DNA or RNA or hybrids thereof.
24. The use of claim 22, wherein the small molecule is a lipid.
25. The use of claim 22, wherein the polypeptide is a protein or a fusion protein comprising a methylation site.
26. The use of any one of claims 21 to 25 wherein the methyltransferase is a methyltransferase as defined in any one of claims 9 to 14.
27. A method for the preparation of a modified target molecule comprising the incubation of the target molecule with the compound of any one of claims 1 to 8 in the presence of a methyltransferase which is capable of using the compound as a cofactor and under conditions which allow the transfer of the compound or of part of it onto the target molecule.
28. The method of claim 27, wherein the methyltransferase is a methyltransferase as defined in any one of claims 9 to 14.
29. The method of claim 27 or 28, wherein the target molecule is as defined in any one of claims 22 to 25.
30. Modified target molecule obtainable by the method of any of claims 27 to 29.

Fig. 1




2/12

Fig. 2A



3/12


Fig. 2B



4/12

Fig. 3

M·Hhal, 2



5/12

Fig. 4






Fig. 5




7/12

Fig. 6A




8/12

Fig. 6B




9/12

Fig. 7A




10/12

Fig. 7B




11/12

Fig. 8A



12/12

Fig. 8B



INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/05405

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07H19/167 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07H C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	PIGNOT, MARC; SIETHOFF, CHRISTOPH; LINSCHIED, MICHAEL; WEINHOLD, ELMAR: "Coupling of a nucleoside with DNA by a methyltransferase" ANGEW. CHEM., INT. ED., vol. 37, no. 20, 1998, pages 2888-91, XP002120745 the whole document	1-30
A	--- MATTEUCCI, M. D.; WEBB, T. R.: "Synthesis and crosslinking properties of a deoxyoligonucleotide containing N6,N6-ethanodeoxyadenosine" TETRAHEDRON LETT., vol. 28, no. 22, 1987, pages 2469-72, XP002120746 --- -/-	

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
"&" document member of the same patent family

Date of the actual completion of the international search

28 October 1999

Date of mailing of the international search report

17/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bardili, W

INTERNATIONAL SEARCH REPORT

International Application No

PC 1/EP 99/05405

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MCCLELLAND, M.: "Purification and characterization of two new modification methylases"</p> <p>NUCLEIC ACIDS RES.,</p> <p>vol. 9, no. 24, 1981, pages 6795-6804,</p> <p>XP002120747</p> <p>cited in the application</p> <p>-----</p>	

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

4

Applicant's or agent's file reference B 2286 PCT	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/EP99/05405	International filing date (day/month/year) 28/07/1999	Priority date (day/month/year) 29/07/1998
International Patent Classification (IPC) or national classification and IPC C07H19/167		
Applicant MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG D...et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 6 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 21/02/2000	Date of completion of this report 02.11.2000
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Bardili, W Telephone No. +49 89 2399 2132 

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP99/05405

I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).):*

Description, pages:

1-30 as originally filed

Claims, No.:

1-30 as originally filed

Drawings, sheets:

1/8-8/8 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 29.1(a)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP99/05405

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 20-26 in respect of industrial applicability.

because:

- ☒ the said international application, or the said claims Nos. 20-26 relate to the following subject matter which does not require an international preliminary examination (*specify*):
see separate sheet

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

- ☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination report cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the standard.
- ☐ the computer readable form has not been furnished or does not comply with the standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims 1-30

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP99/05405

	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-29
	No:	Claims	30
Industrial applicability (IA)	Yes:	Claims	1-19,27-30
	No:	Claims	

2. Citations and explanations
see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

Section III:

Claims 20-26 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT since the description mentions that the claimed compounds could be used as pharmaceuticals (cf. page 18). Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

Section V:

Tetrahedr. Lett. 28, 2469-72 (1987) details the preparation of an aziridine adenosine derivative which may be used to crosslink complementary strands of DNA. The aziridine ring is located at the nucleobase of the adenosine derivative. On the other hand, the compounds of claim 1 have an aziridine ring in 5'-position of the adenosine. The claimed compounds are therefore novel over the prior art.

The subject-matter according to claims 1 to 29 also possesses inventive step because the application demonstrates for the first time that a larger group than a methyl can be transferred to a substrate in a methyltransferase-catalysed reaction. The application discloses how this finding may be used to label DNA. Inventive step is therefore acknowledged.

Since claim 30 relates to a broad class of compounds, which are not defined by structural features, it inevitably includes compounds for which a meaningful technical use is not apparent. Compounds as such, however, are not deemed inventive. Thus, in so far as claim 30 is concerned, the application lacks inventive step.

For the assessment of the present claims 20 to 26 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow,

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP99/05405

however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Section VII:

The literature Tetrahedr. Lett. 28, 2469-72 (1987) should be mentioned in the description of the application as prior art pursuant to Rule 5.1 ii) PCT.